Veru reports fiscal 2023 third quarter financial results

Company receives further regulatory clarity from fda on phase 3 enablar-2 study. potential for enobosarm +/- abemaciclib accelerated approval pathway in metastatic breast cancer, if successful based on new fda guidance

VERU Ratings Summary

VERU Quant Ranking